Near a 12-year low, Kimberly-Clark may be one of the best deep value stocks for income investors to buy in 2026.

Kimberly-Clark’s fourth quarter results reflected a steady performance in a challenging consumer environment, with revenue in ...

Kimberly-Clark announced Monday it's struck an agreement to buy Kenvue in a deal valued at $48.7 billion. The combined company would bring together brands like Huggies and Kleenex with the likes of ...

Kimberly-Clark and Kenvue shareholders have overwhelmingly approved the proposed acquisition of Kenvue. The vote clears a key procedural step toward combining the two businesses into a single health ...

Kimberly-Clark is buying Kenvue, the maker of Tylenol, in a deal worth more than $48 billion, the companies announced on Nov. 3. The deal, which has been approved by each company's board of directors, ...

Kimberly-Clark will buy Kenvue for $48.7 billion. A merged Kimberly-Clark-Kenvue could have $32 billion in annual sales and profits as high as $5.5 billion. At Kimberly-Clark's current $40 billion ...

Household products company Kimberly-Clark (NYSE:KMB) met Wall Streets revenue expectations in Q4 CY2025, but sales were flat ...

Household products company Kimberly-Clark (NYSE:KMB) in Q4 CY2025, but sales were flat year on year at $4.08 billion. Its non ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company.Kenvue shareholders will receive $3.50 per share in ...